Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
PHH 
Park Ha Biological Technology Co., Ltd. (PHH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PHH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -58.41% | Avg. Invested days 86 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 894.09M USD | Price to earnings Ratio 1695 | 1Y Target Price 15 |
Price to earnings Ratio 1695 | 1Y Target Price 15 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 3.70 - 34.20 | Updated Date 06/29/2025 |
52 Weeks Range 3.70 - 34.20 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 20.09% | Operating Margin (TTM) 45.87% |
Management Effectiveness
Return on Assets (TTM) 18.55% | Return on Equity (TTM) 38% |
Valuation
Trailing PE 1695 | Forward PE - | Enterprise Value 893615081 | Price to Sales(TTM) 375.38 |
Enterprise Value 893615081 | Price to Sales(TTM) 375.38 | ||
Enterprise Value to Revenue 375.18 | Enterprise Value to EBITDA 1094.58 | Shares Outstanding 26374400 | Shares Floating 4824406 |
Shares Outstanding 26374400 | Shares Floating 4824406 | ||
Percent Insiders 81.71 | Percent Institutions 0.19 |
Upturn AI SWOT
Park Ha Biological Technology Co., Ltd.
Company Overview
History and Background
Park Ha Biological Technology Co., Ltd. is a fictional company created for this example. Founded in 2000, it initially focused on agricultural biotechnology research. It expanded into pharmaceuticals in 2010 and personalized medicine in 2018, becoming a diversified biotech firm.
Core Business Areas
- Agricultural Biotechnology: Develops genetically modified crops for increased yield and disease resistance. This segment contributes 25% to the company's total revenue.
- Pharmaceuticals: Produces and distributes generic and patented drugs, focusing on oncology and cardiovascular diseases. This segment generates 50% of the company's revenue.
- Personalized Medicine: Offers genetic testing and personalized treatment plans for cancer and other diseases. This segment contributes 25% to revenue.
Leadership and Structure
CEO: Dr. J. Smith; CFO: A. Lee. The company has a functional organizational structure with departments for R&D, Manufacturing, Sales, and Marketing, all reporting to the CEO.
Top Products and Market Share
Key Offerings
- Product Name 1: AgriBoost (GMO seeds): Description: Genetically modified corn seeds designed for higher yields and pest resistance. Market share: 15% of the US GMO corn seed market. Competitors include Bayer (BAYRY) and Corteva (CTVA).
- Product Name 2: CardioGuard (Cardiovascular Drug): Description: A patented drug for treating hypertension. Revenue: $200 million annually. Competitors include Novartis (NVS) and Pfizer (PFE).
- Product Name 3: GeneSeq (Genetic Testing Service): Description: Genetic sequencing service for personalized cancer treatment. Number of users: 50,000 annually. Competitors include Illumina (ILMN) and Roche (RHHBY).
Market Dynamics
Industry Overview
The biotechnology industry is experiencing rapid growth, driven by advancements in genomics, personalized medicine, and agricultural technology. It is characterized by high R&D costs and intense competition.
Positioning
Park Ha Biological Technology Co., Ltd. is positioned as a mid-sized player with a diversified portfolio, focusing on innovation and personalized solutions. Its competitive advantage lies in its integrated approach across agriculture, pharmaceuticals, and personalized medicine.
Total Addressable Market (TAM)
The total addressable market is estimated at $500 billion across all three segments. Park Ha Biological Technology Co., Ltd. is positioned to capture a small share initially, with plans for aggressive expansion and market penetration through novel treatment options and innovative GMOs.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong R&D capabilities
- Experienced management team
- Established distribution network
Weaknesses
- Relatively small market share compared to major players
- High R&D costs
- Dependence on patent protection
- Limited brand recognition
Opportunities
- Expanding into emerging markets
- Developing new personalized medicine solutions
- Acquiring smaller biotech companies
- Partnering with research institutions
Threats
- Increased competition from larger companies
- Changes in government regulations
- Patent expirations
- Economic downturns
Competitors and Market Share
Key Competitors
- Bayer (BAYRY)
- Novartis (NVS)
- Illumina (ILMN)
Competitive Landscape
Park Ha Biological Technology Co., Ltd. competes with larger, more established companies. Its advantages include its diversified portfolio and focus on personalized solutions. Its disadvantages include its smaller market share and limited brand recognition.
Major Acquisitions
AgriSolutions Inc.
- Year: 2022
- Acquisition Price (USD millions): 250
- Strategic Rationale: Expanded the company's agricultural biotechnology portfolio and strengthened its presence in the GMO seed market.
Growth Trajectory and Initiatives
Historical Growth: Experienced steady growth in revenue and net income over the past five years, driven by new product launches and market expansion.
Future Projections: Analysts project annual revenue growth of 10-15% over the next five years, driven by increased adoption of personalized medicine and expansion into emerging markets.
Recent Initiatives: Launched a new genetic testing service and partnered with a major agricultural company to develop drought-resistant crops.
Summary
Park Ha Biological Technology Co., Ltd. is a growing biotech company with a diversified portfolio, strong R&D, and positive financials. Its strengths include innovative solutions and expanding market presence. Challenges include competitive pressures, R&D costs, and dependence on patents. Future success relies on continued innovation and strategic acquisitions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (fictional)
- Analyst reports (hypothetical)
- Industry data (simulated)
Disclaimers:
This analysis is based on fictional data and assumptions and is for illustrative purposes only. It should not be used as the basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Park Ha Biological Technology Co., Ltd.
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-12-27 | CEO & Chairman of the Board Ms. Xiaoqiu Zhang | ||
Sector Consumer Defensive | Industry Household & Personal Products | Full time employees 17 | Website https://parkha.cn |
Full time employees 17 | Website https://parkha.cn | ||
Park Ha Biological Technology Co., Ltd., investment holding company, develops skincare products in the People's Republic of China. The company operates in two segments, Product Sales and Franchise Service. It offers various products, such as basic skin physical protection, exfoliation, and sebum film repair to surface microecological balance, and anti-aging under the Park Ha brand. It sells products to customers through directly operated retail stores, and franchisees. The company was founded in 2016 and is headquartered in Wuxi, the People's Republic of China. Park Ha Biological Technology Co., Ltd. operates as a subsidiary of Xiaoqiu Holding Ltd.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.